Spinraza’s sales were a bright spot in Biogen’s second-quarter earning call this month — and that’s very good news for the University of Massachusetts.
A university spokesperson could not confirm the exact amounts and Biogen (BIIB) did not respond to a request for comment. However, based on figures provided by one of the inventors, STAT estimated that the university has received about $10.5 million since the FDA approved the drug for spinal muscular atrophy in December 2016.
About the Author Reprints
